-
| Exchange | NASDAQ |
|---|---|
| CurrencyCode | USD |
| ISIN | US69562K5065 |
| Sector | Other |
| Industry | Other |
| Beta | nan |
|---|---|
| Market Cap | None |
| PE Ratio | None |
| Target Price | 23.75 |
| Dividend Yield | 0.0% |
Pain Therapeutics, Inc. develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease. The company was founded in 1998 and is based in Austin, Texas.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PTIE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025